Many Patients Retain Weight Loss After Discontinuing GLP-1 Drugs, Real-World Data Reveals

Spread the Message

Read Time:3 Minute, 33 Second

New U.S. research analyzing millions of patient records suggests that a significant portion of individuals using GLP-1 drugs like Wegovy and Zepbound maintain or continue losing weight even after stopping treatment. Published January 22, 2026, by nference, the study challenges clinical trial findings showing rapid weight regain and highlights the role of exercise counseling in sustaining results. This development could reshape obesity management strategies amid soaring demand for these medications.

Key Findings from the Study

nference researchers used AI to examine 14 million physician notes and 15 million clinical records from over 135,000 patients treated with GLP-1 drugs for at least one year. Among 1,615 tirzepatide users who discontinued, six months later, 36% maintained their weight loss, 36% lost additional weight, and only 28% regained, contrasting sharply with Novo Nordisk’s trials where two-thirds regained weight.

Patients receiving exercise guidance post-discontinuation were nearly twice as likely to sustain losses compared to those without. Factors linked to regain included anxiety, anemia, thyroid fluctuations, depression, and post-stop antibiotics, though causation remains unclear. Venky Soundararajan, nference’s Chief Scientific Officer, noted, “The implications suggest durability can be achieved under routine care,” proposing personalized strategies like intermittent dosing.

Contrasting Clinical Trial Evidence

Randomized trials from Novo Nordisk and others show substantial regain after stopping GLP-1s; for instance, semaglutide users regained about two-thirds of lost weight within a year. A University of Oxford review of 37 studies with over 9,300 participants found regain at 0.3 kg per month faster than behavioral programs alone.

Real-world differences may stem from gradual tapering, smaller initial losses, or ongoing lifestyle efforts absent in trials. Dr. David Kessler, former FDA commissioner who used GLP-1s, emphasized, “It’s not the drugs that lead to lasting weight loss. It ultimately depends on whether individuals learn to modify their eating habits.” Eli Lilly and Novo declined direct comment on the nference data.

Expert Commentary and Perspectives

Experts caution the nference study is observational, pending peer review, and lacks details on dosing, comorbidities, or full lifestyle data, making it less robust than trials. Hamlet Gasoyan, PhD, from Cleveland Clinic, explained real-world patients often pursue diet changes or switch medications post-stop, unlike abrupt trial halts.

Adam Collins, associate professor at University of Surrey, noted GLP-1s may reduce natural hormone sensitivity, heightening overeating risk off-drug. Despite optimism, many urge lifelong therapy for obesity as a chronic condition, per WHO guidelines recommending GLP-1s long-term alongside behavioral support. Dr. Rick Pumill of Cross County Cardiology views them as first-line for high heart risk, citing 15-20% losses with semaglutide.

Public Health Implications

With over 1 billion obese globally and U.S. prescriptions surging, these findings suggest GLP-1s enable “off-ramps” for some, potentially easing supply strains and costs nearing $1,000 monthly. Sustained losses could cut cardiometabolic risks; GLP-1s reduce heart events and improve glycemic control.

For patients, pairing drugs with exercise and habit changes offers practical paths to durability—strength training counters 15-40% muscle loss during use. Policymakers face equity challenges; WHO stresses affordable access to avoid disparities. Real-world success implies comprehensive care models integrating pharma with lifestyle for scalable impact.

Limitations and Future Directions

Observational data risks biases, overlooking variables like adherence or diet; trials provide gold-standard control. nference analyzed tirzepatide mainly, limiting semaglutide generalizability. Long-term safety data lags, with WHO noting insufficient follow-up beyond 3.5 years.

Ongoing trials and AI analytics promise predictors of “super-responders” (15%+ loss). Future research must clarify metabolic changes persisting post-drug, like altered fat-burning. Balanced use avoids over-reliance, emphasizing obesity’s multifactorial nature.

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.